(AOF) – Nanobiotix (+ 22.56% to 8.80 euros)
Nanobiotix is gone. The biotech announced this morning the recruitment of the 1st patient as part of its pivotal phase 3 study in its main program in head and neck cancer (T&C). The study is designed for worldwide registration, to assess the efficacy and safety of radiotherapy-activated NBTXR3 with or without cetuximab vs. radiotherapy alone with or without cetuximab in nearly 500 high-risk elderly patients ineligible for treatment. chemotherapy, with locally advanced T&C squamous cell carcinoma.
© AOF
Legal disclaimer
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights owned by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial or non-commercial exploitation, creation of hypertext link or reuse in any way whatsoever of this information is subject to the prior written agreement of OPTION FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from sources it considers the most reliable. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of errors and defects, even hidden, nor the exhaustiveness or lack of conformity for any use whatsoever of these data and of OPTION FINANCE. SAS or one of its contributors, and cannot be held responsible for delays or interruptions that could affect access to them. The user of the OPTION FINANCE SAS service will use AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember about financial markets.